Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.
Contact us to learn how Vital Transformation can help your organisation.
LATEST RESEARCH
LATEST COMMUNICATIONS
![bsbh-vt-logo-x2](https://vitaltransformation.com/wp-content/uploads/2018/05/bsbh-vt-logo-x2-300x58.png)
Our Communication Services
With the continuing pressure placed upon the US biopharma sector from Washington DC, how is the California biopharma ecosystem, arguably the leading hub for innovative biotech worldwide, responding? In this Vital Health Podcast, we speak with Joseph Panetta to discuss this issue. Joe is the President & CEO of Biocom California, an organization representing over 1,800 members working in California's life sciences sector to break down barriers to doing business and advocate for innovation. As the head of Biocom California since 1999, Joe is regarded as a thought leader in biotech and life sciences globally.
Find all our communication projects on Better Science, Better Health
MORE RESEARCH
Database Exploitation Could Slash Clinical Trial Durations, Cut Costs
29th October, 2014
A presentation by health care consultancy VitalTransformation shows that a fifth could be cut off clinical trial times and up to $300 million saved if databases were used for trial recruitment.
Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law
19th May, 2014
Abstract
Eroom’s Law is, literally, Moore’s law in reverse. The pharmaceutical sector invests $50 billion annually in research for new medicines but, “the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms”. Pharmaceutical companies have invested enormous sums in new molecular entities (NME) in the areas of unmet medical need identified by the World Health Organization (WHO), but the approval rates from phase I are only 7% for cardiovascular disease, dropping to 4% for Alzheimer’s disease.
Whole-Body Magnetic Resonance Angiography (WBMRA) as a tool for driving efficiency in the cost and treatment of Claudication Comorbities
12th September, 2013
Abstract
Whole-Body Magnetic Resonance Angiography (WBMRA) consists of a contrast-enhanced Magnetic Resonance Angiogram (MRA) scan of the entire body in a single step. In the diagnosis of cardiovascular co-morbidities in Peripheral Arterial Disease (PAD), the utilization of WBMRA can streamline the diagnostic process by minimizing the usage of MRA, CT, and Angiograms. In this work, the potential cost savings to the hospital by using WBMRA in PAD are modeled based on collected data that accounts for all interventions in the radiological department of a set of 50 patients with Claudication in the period 2008–2012 at Ninewells Hospital (NHS Tayside).
VITAL HEALTH PODCASTS
Our podcast series is also available via your favourite channels!
![]() |
![]() |
---|---|
![]() |
![]() |
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more...
VT on X
EU biopharma company startups declined 50% in 2018, well before the COVID pandemic #gplhttps://t.co/issED0DVJV@amgen @abbvie @abbvieuk @IAmBiotech @DuaneSchulthess @BSBHbyVT @VitalTransform pic.twitter.com/fORbCktE8z
— VitalTransformation (@VitalTransform) April 23, 2024
New study "The EU General Pharmaceutical Legislation & Clawbacks: Calculated impacts – both designed and unintended." https://t.co/issED0DnUn@amgen @AbbVie @IAmBiotech @DuaneSchulthess @BSBHbyVT @VitalTransform @abbvieuk
— VitalTransformation (@VitalTransform) April 18, 2024
Our clients include many of the world’s leading health care organisations.